Ambit
Driving breakthroughs in cancer and inflammatory disease treatment through pioneering kinase inhibitor research and innovative clinical collaborations.
General Information
Get notified when Ambit moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Discover More
About Ambit
Taxonomy: biopharmaceutical, kinase inhibitors, cancer treatment, inflammatory disease, clinical trials, FLT3 inhibitor, oncology, Astellas Pharma Inc., small molecule drugs, AC220, AC480, AC430, JAK2 inhibitor, preclinical pipeline, drug discovery
Funding Rounds & Investors (10)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | •••••• | 9 |
|
06 Nov 2012 |
| Series D | •••••• | 9 |
|
10 Jun 2011 |
| Debt Financing | •••••• | - | 15 Oct 2010 | |
| Series D | •••••• | - | 15 Apr 2010 | |
| Debt Financing | •••••• | - | 05 Jun 2009 |
Ambit Alternatives & Competitors
Innovative therapies for dermatological conditions with unmet medical needs
Dedicated to advancing cancer treatment through innovative MEK kinase inhibitors.
Developing deuterated BEST in CLASS MET kinase Inhibitor
vs
Deciphera Pharmaceuticals
FAQ About Ambit
Don't just browse. Track.
Signal Tracker monitors Ambit and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.